Bio Seeing Early Life After ASCO 2022 & Big Acquisitions
Insights - The bio sector is seeing some life with improved fundamentals, which could be an early sign of reversal. ASCO in Chicago is wrapping up and … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Will MDNA11 Cohort 3 Promising Biomarkers Translate to Responses?
Insights - Yesterday, Medicenna released additional data for their IL-2 program MDNA11. The 3rd cohort (n=4) used a dose of 30 µg/kg (IL-2 content of 6 µg/kg). Remember, MDNA11 is … Continue Reading
Premium
First Look At Genocea’s GEN-011 Data Underwhelms
Insights - Genocea (GNCA) reported underwhelming data at AACR for their targeted TIL approach, GEN-011. Remember, Genocea was using neoantigen reactive T-cells drawn from the peripheral blood … Continue Reading
Premium
AFMD13+NK Data Continues Impressing at AACR22
Insights - Affimed & MD Anderson reported an update on their AFM13+NK cell program. The data was very promising and exceeded expectations with continued dose response and durability. The Data … Continue Reading
Premium
What Nektar’s IL-2 Flop Means For Space
Insights - Big news this week in bio land is that Nektar/Bristol Myers IL-2 drug failed to benefit patients with melanoma. The primary endpoints of overall survival (OS) and … Continue Reading
PremiumMedicenna CSO Leaves In Midst of Ongoing Phase 1
Insights - Yesterday, Medicenna (MDNA) announced a clinical advisory board and strategic advisors. In the end of the press release, MDNA disclosed that Chief Scientific Officer Dr. Kevin Moulder … Continue Reading
Premium
9Meters Delays SBS Data Yet Again
Insights - 9 Meters Bio (NMTR) shared yesterday that their topline results for Phase 2 in Short Bowel Syndrome (SBS) will be pushed back to Q2 2022. … Continue Reading
Premium